Theralink® Technologies closer to potentially becoming the Standard of Care in Breast Cancer
George Mason University and Rutgers Cancer Institute of New Jersey Name Theralink Technologies as the Commercial Provider of Critical Assay DENVER – February 22, 2021 – In a recent announcement by Rutgers Cancer Institute of New Jersey and the Center for Applied Proteomics and Molecular Medicine at George Mason University (CAPMM), Theralink Technologies (OTC: OBMP) […]
Theralink® Technologies Announces Milestone Event—The Commencement of Testing on its First Patients
DENVER, Colorado — January 27, 2021 — Theralink® Technologies (OTC: OBMP) (“Theralink” or the “Company”), a precision medicine molecular profiling company with a novel phosphoprotein-based Laboratory Developed Test (LDT), today announced that it has begun the testing of its first patients with the Theralink’s Reverse Phase Protein Array (RPPA) technology. Theralink’s RPPA testing measures the […]
Theralink® Technologies Issues Letter to Shareholders
DENVER, Colorado — January 6, 2021 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today issued a letter to shareholders from its President and CEO, Mick Ruxin, M.D., providing a 2020 year-end recap and vision for the path ahead […]
Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.
DENVER, Colorado — November 16, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a precision oncology molecular profiling company with a novel phosphoprotein-based laboratory developed test (LDT), today announced its partnership with Perthera, a market leader in Precision Oncology technology and services. The alliance will facilitate and accelerate access to Theralink’s 32 phosphoprotein panel, […]